Yagi Yusuke, Doke Akito, Iwame Saya, Arakawa Yu, Yamagishi Yuka
Department of Infection Prevention and Control, Kochi Medical School Hospital, Nankoku, Kochi, Japan.
Department of Pharmacy, Kochi Medical School Hospital, Nankoku, Kochi, Japan.
Infect Drug Resist. 2024 Jun 4;17:2237-2247. doi: 10.2147/IDR.S459708. eCollection 2024.
Methicillin-resistant (MRSA) enteritis is a condition in which MRSA grows abnormally in the intestine after administration of antimicrobial agents, resulting in enteritis. Patients with MRSA detected in stool culture tests are often diagnosed with MSRA enteritis. However, uncertainty remains in the diagnostic criteria; therefore, we conducted epidemiological studies to define these cases.
Patients who tested positive for MRSA by stool culture using selective media 48 h after admission to Kochi Medical School Hospital between April 1, 2012, and December 31, 2022, and did not meet the exclusion criteria were included. We defined MRSA enteritis (Group A) as cases that were responsive to treatment with vancomycin hydrochloride powder, had a Bristol Stool Scale of ≥ 5, and a stool frequency of at least three times per day; all others were MRSA carriers (Group B). Multivariate analysis was performed to risk factors associated with MRSA enteritis.
Groups A and B included 18 (25.4%) and 53 (74.6%) patients, respectively. Multivariate logistic regression analysis showed that a white blood cell count of > 10000/µL (odds ratio [OR], 5.50; 95% confidence interval [CI], 1.12-26.9), MRSA count of ≥ 2+ in stool cultures (OR, 8.91; 95% CI, 1.79-44.3), and meropenem administration within 1 month of stool specimen submission (OR, 7.47; 95% CI, 1.66-33.6) were risk factors of MRSA enteritis.
The case definitions reviewed for MRSA enteritis may be useful as diagnostic criteria.
耐甲氧西林金黄色葡萄球菌(MRSA)肠炎是指在使用抗菌药物后,MRSA在肠道内异常生长,从而导致肠炎的一种病症。粪便培养检测出MRSA的患者常被诊断为MRSA肠炎。然而,诊断标准仍存在不确定性;因此,我们开展了流行病学研究以明确这些病例。
纳入2012年4月1日至2022年12月31日期间入住高知医科大学医院48小时后使用选择性培养基进行粪便培养MRSA检测呈阳性且不符合排除标准的患者。我们将对盐酸万古霉素粉末治疗有反应、布里斯托大便分类法为≥5级且每日排便频率至少三次的病例定义为MRSA肠炎(A组);其他所有病例为MRSA携带者(B组)。对与MRSA肠炎相关的危险因素进行多变量分析。
A组和B组分别包括18例(25.4%)和53例(74.6%)患者。多变量逻辑回归分析显示,白细胞计数>10000/µL(比值比[OR],5.50;95%置信区间[CI],1.12 - 26.9)、粪便培养中MRSA计数≥2+(OR,8.91;95% CI,1.79 - 44.3)以及在提交粪便标本后1个月内使用美罗培南(OR,7.47;95% CI,1.66 - 33.6)是MRSA肠炎的危险因素。
所审查的MRSA肠炎病例定义可能有助于作为诊断标准。